- Company
- Pharmacist's No. 1 product among athlete's foot tx, Tiersil
- by Lee, Seok-Jun Jun 25, 2020 07:02am
- The pharmacist's recommendation for 'once-form athlete's foot treatment' was found to be due to patient convenience (40.4%), medication compliance, and therapeutic effect (39.9%). The pharmacist's No. 1 product among athlete's foot fungus drugs was investigated as 'Tiersil Once (Terbinafine Hydrochloride)’. Dailypharm conducted an online su
- Company
- Hanmi Science Presents 6 Great Visions for Post COVID-19
- by dailypharm Jun 25, 2020 06:09am
- Hanmi Science with the gene of 'Innovation' presented six great visions for the post COVID-19. Hanmi Science's 6 visions, abbreviated as 'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral Bio','City Bio','Green Bio', and 'Marine Bio'. For the vision business, CEO Chong-Yoon Lim promised to raise outstanding employees’ an
- Company
- Sanofi to dismiss 3 sales reps breaching compliance
- by An, Kyung-Jin Jun 25, 2020 06:08am
- Accused of false reporting client visits, three sales reps from Sanofi-Aventis Korea may be dismissed as recommended by the headquarters. The sales department seems to be stirred by the management and commented, “The management has made a harsh decision disregarding the possibility of system error.” The sign of internal dispute is appa
- Company
- Hanmi's Gugu was released in Japan
- by Chon, Seung-Hyun Jun 25, 2020 06:08am
- Hanmi's erectile dysfunction treatment 'Gugu' was released in Japan as a treatment for prostate hyperplasia. According to Hanmi on the 23rd, Sandoz began to sell Gugu 2.5mg and 5mg from all over Japan on the 18th. The Japanese product name is “Sandoz Tadalafil” (Tadalafil Tablets 2.5mg&8729;5mg ZA SANDOZ). Gugu is generic for Cialis,
- Company
- COVID-19 devastates outpatient prescription in April-May
- by Chon, Seung-Hyun Jun 25, 2020 06:07am
- Top pharmaceutical companies have been struggling with outpatient prescription sales for two consecutive months. The COVID-19 seems to have slowed down drug prescription for nine out of ten major pharmaceutical companies in last two months and impacted the overall prescription volume this year. On June 22, pharmaceutical market research firm
- Company
- COVID-19's budget is being delayed in the National Assembly
- by Nho, Byung Chul Jun 24, 2020 06:14am
- With the global spread of COVID-19, vaccines and treatments are urgently needed, and the government's promised support budget plan is not in progress. Unlike the fast and full support in developed countries, there is concern that the support may be delayed and the golden time to overcome COVID-19 may be missed. As of the 23rd, 15 dome
- Company
- Penmix in trial to evade patent on fat dissolving Belkyra
- by Nho, Byung Chul Jun 24, 2020 06:14am
- An injection CDMO Penmix (CEO Park Dongkyu) succeeded in evading patent on Allergan’s under-chin fat reducing injection Belkyra (desoxycholic acid). On June 19, Intellectual Property Trial and Appeal Board validated the negative confirmation of patent scope on Belkyra’s desoxycholic acid and other pharmaceutical substance based on the
- Company
- Patients with Ultracet don't get benefit for anticancer drug
- by Eo, Yun-Ho Jun 23, 2020 06:21am
- There have been cases that do not meet the intention of the original insurance benefit standard in the treatment of prostate cancer. Targeted anticancer drug options such as 'Zytiga (Abiraterone acetate)' and 'Xtandi (Enzalutamide)' currently exist in adult resistant castration resistant prostate cancer (mCRPC). Moreover, since last May, t
- Company
- Immunotherapies tap on SCLC treatment area for more options
- by Eo, Yun-Ho Jun 23, 2020 06:21am
- One after another, immunotherapies are tapping into the unexplored small cell lung cancer (SCLC) treatment area. According to the pharmaceutical industry sources on June 20, AstraZeneca’s Imfinzi (duvalumab), following Tecentriq (atezolizumab) by Roche, has been indicated as a first-line treatment for SCLC by Korea’s Ministry of Food
- Company
- Daewoong wins first patent dispute in Belkyra after 2 years
- by Kim, Jin-Gu Jun 22, 2020 06:10am
- Daewoong has passed the first gateway for the release of generic for Belkyra (Deoxycholic acid), which targets and eliminates fat cells under the chin. Daewoong won the patent dispute that has been leading for two years with Allergan. The IPT ( Intellectual Property Trial and Appeal Board) made a trial decision on the 19th at Daewoong P
